Dr Reddys Laboratories Ltd — Q1FY27 earnings call summary

Filed 15 July 2026 · Official transcript

Demand remains strong; 6-7 million pens supply targeted between Q3 and Q4 FY27
Commercial supply halted until validation completes, expected by late September; supply to resume October-November
No penalties expected for supply delays; long-term partnership with OneSource maintained
Semaglutide API scale-up batch showed impurity out of specification, requiring process revalidation
No impact on existing market supplies or patient safety; no recall needed for marketed batches
Backup API supplier qualification underway, but pre-approval supplement will take about a year
Potential inventory write-down at OneSource due to halted batches